ABSTRACT

Regenerative medicines offer the prospect of treating medical conditions that require the replacement, repair, or regeneration of damaged cells and tissues and thereby have the potential to restore bodily functions. For the –rst time, we can look forward to tackling medical conditions that hitherto have been intractable to conventional approaches. Furthermore, by targeting the underlying causes of disorders, regenerative medicines offer the opportunity to better manage chronic conditions, possibly even leading to cures. It is therefore unsurprising that their potential has attracted a signi–cant level of attention by a wide range of professionals, governments, and members of the general public. However, the question remains whether their support is suf–cient to ensure the delivery of regenerative medicines to patients in a timely fashion and on a routine basis. Key to the delivery of any therapeutic is an appropriate level of –nancial commitment and this chapter sets out to review some of the trends and drivers that motivate both public and private investors to invest in the regenerative medicine industry.